Literature DB >> 32452526

Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis.

Eliza M Lauer1, Miguel Waterhouse1, Moritz Braig2, Jurik Mutter1, Sabine Bleul1, Jesús Duque-Afonso1, Justus Duyster1,3, Reinhard Marks1, Peter C Reinacher4,5, Marco Prinz6,7,8, Gerald Illerhaus9, Jürgen Finke1, Elisabeth Schorb1, Florian Scherer1,3.   

Abstract

Entities:  

Keywords:  BTK inhibition; Ibrutinib; central nervous system lymphoma; real-world analysis; relapsed/refractory disease

Year:  2020        PMID： 32452526     DOI： 10.1111/bjh.16759

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  3 in total

1.  Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery.

Authors:  Matthew R Wilson; Toby A Eyre; Nicolas Martinez-Calle; Matthew Ahearne; Katrina E Parsons; Gavin Preston; Jahanzaib Khwaja; Jeremy Schofield; Johnathon Elliot; Almurtadha Mula Kh; Nimish Shah; Cheuk-Kie Cheung; Matthew A Timmins; Thomas Creasey; Kim Linton; Jeffery Smith; Christopher P Fox; Fiona Miall; Kate Cwynarski; Pamela McKay
Journal:  Blood Adv       Date:  2020-08-11

Review 2.  Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review.

Authors:  Gaurav Nepal; Mahika Khurana; Domenica Herrera Bucheli; Siddhartha Bhandari; Utsav Joshi; Riwaj Bhagat; Jessica Holly Rehrig; Prasun Pudasainee; Yow Ka Shing; Juan Fernando Ortiz; Rajeev Ojha; Bikram Prasad Gajurel; Jonathan Quinonez; Samir Ruxmohan; Trevine Albert; Steven Licata; Joel Stien
Journal:  Neurol Int       Date:  2022-01-11

3.  Efficacy and Safety of Ibrutinib in Central Nervous System Lymphoma: A PRISMA-Compliant Single-Arm Meta-Analysis.

Authors:  Liwei Lv; Xuefei Sun; Yuchen Wu; Qu Cui; Yuedan Chen; Yuanbo Liu
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.